Mukaddes Nahit Motavali, Abali Osman
Istanbul University, Child and Adolescent Psychiatry Department, Medical Faculty of Istanbul, Istanbul, Turkey.
J Child Adolesc Psychopharmacol. 2003 Fall;13(3):295-9. doi: 10.1089/104454603322572624.
The purpose of this study was to investigate the short-term safety and effectiveness of quetiapine in the treatment of children and adolescents with Tourette's disorder.
This was an 8-week, open-label trial that included 12 subjects with a mean age of 11.4 +/- 2.4 years. The subjects were seen every week throughout the study.
Clinical responses, as measured by the Turkish version of the Yale Global Tic Severity Scale, revealed a statistically significant reduction in tic scores ranging from 30-100%. Mean dose of quetiapine at the end of the study was 72.9 +/- 22.5 mg/day. Three subjects complained of sedation in the first week of treatment.
The favorable results of this open-label study should be interpreted with caution due to the uncontrolled nature of the study. Spontaneous waxing and waning of symptoms should also be considered. Further controlled studies are required.
本研究旨在调查喹硫平治疗儿童和青少年抽动秽语综合征的短期安全性和有效性。
这是一项为期8周的开放标签试验，纳入了12名平均年龄为11.4±2.4岁的受试者。在整个研究过程中，每周对受试者进行观察。
通过耶鲁全球抽动严重程度量表土耳其语版测量的临床反应显示，抽动评分有统计学意义的降低，降低幅度为30%-100%。研究结束时喹硫平的平均剂量为72.9±22.5毫克/天。三名受试者在治疗的第一周抱怨有镇静作用。
由于本研究的非对照性质，对这项开放标签研究的良好结果应谨慎解读。还应考虑症状的自然波动。需要进一步的对照研究。
